Kornimate/medical-research-clean huggingface dataset:
effects of optimizing nocturnal glycemic control on sleep parameters in type 1 diabetes

Conditions: Type 1 Diabetes

Summary: sleep is crucial for physical and mental health. environmental, social, or professional pressures can cause sleep duration to fall below the recommended 7-9 hours of sleep per night. young adults with type 1 diabetes, have additional interference with fear, control and management of hypo/hyperglycemia management, alarms from their devices, which delay bedtime, disrupt sleep and generate multiple awakenings and difficulty returning to sleep. sleep disturbance is correlated with blood glucose variability as recently demonstrated by a coupled analysis of sleep and glucose level collected by continuous glucose monitoring (cgm). in this study, higher glucose variability predicted impaired sleep at the individual level. automated insulin infusion has shown impressive results in clinical and real-life studies, with more than 90% of patients achieving good glycemic control. il seems to improve sleep quality in subjects after 4 weeks in hybrid closed-loop, self-administered studies compared to a control group. the main objective of our study is to measure the positive influence of a better glycemic control on the different sleep parameters in subjects with type 1 diabetes at the time of the passage in hybrid closed-loop and in comparison to an identical period in open-loop.


Eligibility criteria:
inclusion criteria: * patients usually followed by the diab-ecare service (hcl), male or female, between 18 and 50 years old, * confirmed diagnosis of type 1 diabetes for more than 1 year regardless of age of diagnosis, * eligible according to current recommendations and the center's practices for a hybrid closed-loop solution including all dexcom g6, * on pump, whatever the device used, for at least 6 months and with a dexcom g6 cgm sensor for at least one month with more than 95% of data obtained, * bmi\<30 kg/m2, * hba1c \<10%, * do not oppose to the said research. exclusion criteria: * patients with type 2 diabetes, * patients with a cause other than diabetes that could disrupt sleep: * known or suspected sleep apnea syndrome with high risk according to the berlin questionnaire, and/or * presence of risk factors such as severe retinopathy, nephropathy, hypertension, autonomic neuropathy, chronic psychiatric disorders, endocrine or metabolic pathologies that have not been stabilized, therapeutics that may alter sleep (i.e. sleeping pills, corticosteroids, antidepressants, anxiolytics, antihistamines), regular use of cannabis, abusive use of alcohol (regularly \> 3 drinks per day for a man and \> 2 drinks for a woman) and/or * night or shift work, * inability to collect data and/or understand the objectives of the study according to the investigator, * persons under legal protection, * persons not affiliated with a social security system

Keywords: type 1 diabetes, sleep, nocturnal glycemic control
calcium from fish bone in volunteers with osteopenia

Conditions: Osteopenia

Summary: the aims of this study are to explore efficacy and safety of calcium from fish bone in volunteers with osteopenia. the volunteers are divided into 2 groups which are calcium from fish bone treatment group and calcium carbonate treatment group. both groups received the calciums everyday for 6 months. bone mineral density, blood examination, physical examination, adverse events, and satisfaction are evaluated before and after treatment.

the aims of this study are to explore efficacy and safety of calcium from fish bone in volunteers with osteopenia. the volunteers are divided into 2 groups which are calcium from fish bone treatment group and calcium carbonate treatment group. both groups received the calciums everyday for 6 months. bone mineral density is analyzed before and after treatment. osteocalcin, total procollagen type-1 n-terminal propeptide (p1np), beta-crosslaps, parathyroid hormone (pth), calcium, phosphate level, vitamin d level (serum 25(oh)d), albumin, aspartate transaminase (ast), alanine transaminase (alt), alkaline phosphatase (alp), creatinine (cr), blood urea nitrogen (bun), and complete blood count (cbc) are assessed before and after taking for 3 and 6 months. physical performance and food diary are also tested and records. moreover, adverse effects including skin allergy, gastrointestinal abnormality, respiratory abnormality are evaluated. satisfaction is asked after treatment.

Eligibility criteria:
inclusion criteria: * male age more than 70 years or female age more than 65 years or all age volunteers that have at least 1 risk factors which are menopause before 45 years, menopause with the height reduction (more than 4 cm), body mass index less than 20 kg/mm2, bone fracture history, taking some medicine that has an effect on bone density reduction, have disease that has an effect on bone density reduction, father and mother have bone fracture history, fracture risk assessment tool (frax) in intermediate risk, osteoporosis self-assessment tool for asian (osta) score, khon kaen osteoporosis study (kkos) score in intermediate risk or higher intermediate risk * bone mineral density between -1 to -2.5 * no osteosclerosis * can read and write * willing to be volunteer exclusion criteria: * allergic to calcium, magnesium, phosphorus, zinc, collagen, and osteocalcin * taking calcium or vitamin d with in 14 days before the study start * taking osteosclerosis' medicine * have uncontrolled diseases * pregnancy and lactation * participating in other study

Keywords: osteopenia calcium fish bone efficacy safety
risk factors in heart failure patients with preserved ejection fraction

Conditions: Heart Failure With Preserved Ejection Fraction

Summary: this study aimed to identify the independent risk factors associated with heart failure readmission, cardiac mortality and all-cause death among patients discharged from xiangtan central hospital with heart failure and preserved ejection fraction (hfpef). understanding related risk factors might add future clinical decision making for individualized post discharge management of hfpef patients aiming to improve the outcome of discharged hfpef patients.

this study sought to determine the independent risk factors linked to endpoint events (which include all-cause mortality or readmission for heart failure, cardiovascular death) among hospitalized patients with heart failure and preserved ejection fraction (hfpef) at xiangtan central hospital during the period from may 1, 2014, to january 31, 2023. the clinical follow up ended on january 31, 2024. the study examined the risk factors associated with the endpoint outcome (cardiovascular death and death from any cause and readmission due to heart failure) to provide clinical evidence for intervening discharged hfpef patients, with the objective of improving patient outcomes in future clinical practice. the clinical features of hospitalized heart failure with preserved ejection fraction (hfpef, ef≥50%) are analyzed retrospectively by reviewing the patient's demographic, clinical data, including patient medical history, initial clinical evaluations, and therapeutic interventions, as well as echocardiographic data in the hospital's electronic health records and relevant databases. the clinical outcome of enrolled patients are obtained through a team of three experienced cardiologists and twelve nursing professionals through outpatient consultations, telephone follow-ups, and community visit. the primary endpoint events are all-cause mortality, the second endpoints are the composite cardiovascular death and heart failure readmission.

Eligibility criteria:
inclusion criteria: * patients discharged with diagnosis of heart failure were screened and met definition of heart failure with preserved ejection fraction (hfpef) according to the 2021 european society of cardiology (esc) guidelines at final analysis. * 1）heart failure signs and symptoms; 2）lvef\>50%; exclusion criteria: * 1) age under 18 years; 2) life expectancy of less than one year due to non-cardiac conditions.

Keywords: hfpef, outcome
assessment of the psychophysical state during rehabilitation treatment with lokomat

Conditions: Cerebral Palsy; Acquired Brain Injury; Hereditary Spastic Paraplegia

Summary: the use of robotic technologies in rehabilitation is an increasingly widespread practice in the health sector: the lokomat is a medical device intended for walking rehabilitation, consisting of an exoskeleton, a treadmill and a harness that supports the body weight and acts as a safety tool this technology is useful in the rehabilitation of pathologies such as prenatal stroke, brain injury, paraplegia, multiple sclerosis and other motor, orthopedic and neurological problems. during these treatments, the psychological / emotional component of the patient is not properly considered and the success of the treatment remains focused on the motor-rehabilitation level. the management of subjective-experiential aspects remains in the hand of clinical figures (primarily physiotherapists) who have no tools for objective assessment other than their sensitivity. however, considering the experience is fundamental for the success of the therapy: this happens especially in the pediatric field, where clinical results improve significantly when children start therapy with a relaxed and positive mental state. the aim of this project is to investigate the rehabilitation experience of patients who perform gait rehabilitation by menas of the lokomat system, considering the relationship between physiological parameters and moods. therefore, the main goal is to monitor the patient's psychophysical condition before, during and after the rehabilitation activity, during the different sessions. this will allow describing, with qualitative and quantitative data, the user experience of the patient who undergoes a therapeutic treatment with the lokomat.


Eligibility criteria:
inclusion criteria: - patients that need gait rehabilitation treatment according to their clinician exclusion criteria: * subjects unable to understand and execute simple instructions; * subjects with skin problems in the wrist area intended for the application of the empatica bracelet.
resiliency intervention for patients with als and their care-partners

Conditions: Amyotrophic Lateral Sclerosis (ALS); Emotional Distress

Summary: the purpose of this study is to pilot a resiliency and coping intervention for persons recently diagnosed with amyotrophic lateral sclerosis (als) and their primary informal caregivers. the data investigators gather in this study will be used to further refine our intervention.

the goal of this study to refine our proposed intervention resilient together als (rt-als) through an open pilot. the investigators will deliver an open pilot of the intervention (n= up to10 dyads; up to 20 participants total) to evaluate initial feasibility and acceptability using exit interviews and pre-post assessments. the open pilot will take place over zoom, with participants recruited from the massachusetts general hospital's sean m. healey and amg center for als. study clinicians will deliver 6, 30-45 minute sessions over zoom. all participants will complete measures at baseline and after completion of the program (6 weeks). at the completion of the program, participants will engage in an exit interview where they will provide feedback on the intervention.

Eligibility criteria:
inclusion criteria for patient with als: * recent (within \~2 months) of first appointment at healey center for diagnosis of als documented in epic (based on recommendations from neurologists) * ability to understand the study and research protocol as determined by a standardized teach-back method of assessment * ability to communicate by writing, speaking, or assistive communication device inclusion criteria for dyad: * english speaking adults * dyad lives together * at least one partner endorses clinically significant emotional distress during screening (\>7 on either subscale of the hads) exclusion criteria: * patient with als with comorbid terminal diagnosis or severe mental health disorder that limits ability to participate (by self-report, as determined by our clinical team); * cognitive disorder that limits ability to participate (per neurologist) * inability or unwillingness to use live video technology (will teach any dyads who have low technology literacy how to use live video technology)

Keywords: amyotrophic lateral sclerosis als caregiving coping
stroke team remote evaluation using a digital observation camera

Conditions: Stroke

Summary: the purpose of this trial is to determine if an experimental remote video camera system is an effective way for a stroke specialist to evaluate stroke patients from a distant site.

the stroke team remote evaluation using a digital observation camera (stroke doc) system is a digital video camera system that can transfer video and audio images from the clinic or emergency room to a distant (remote) place where a stroke specialist can review the images in real time (as they happen). this system uses site independent software to access the camera system from multiple locations. the study will determine if video consultation is superior to telephone consultation for remote evaluation or treatment of stroke patients, and the usefulness of this system in evaluating patients with suspected stroke symptoms. however, this method is being used in other fields of medicine for assistance in medical evaluations. participants will be randomly assigned to receive evaluation by either the video camera system or by telephone alone. for those assigned to the video camera system, the system will be activated and will record and transmit video and audio images to a stroke specialist located at a remote location. he/she may ask the participants questions relating to medical illnesses and current symptoms, and may also review laboratory tests and x-ray images using a computer, if available. the stroke specialist will also perform general physical and neurological examinations, which will take place by video camera with the assistance of a bedside physician who will perform the actual examinations. for those participants assigned to the telephone-only consultation, the video system will not be activated, but the same procedure as above will be followed except the stroke specialist will not be able to see the participants or examine them using the video camera system. participation in the study will last for the entire time the participants are in the hospital. participants will be contacted by telephone by a study nurse 3 months post-stroke for a 10-minute interview regarding their current health. the total duration for individual participation is 3 months. the study is part of the specialized program of translational research in acute stroke (spotrias), which allows researchers to enhance and initiate translational research that ultimately will benefit stroke patients.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * symptoms consistent with acute stroke (ischemic or hemorrhagic) * acute presentation of stroke symptoms, per bedside physician discretion (onset generally less than 12 hours and likely less than 3 hours) exclusion criteria: * unlikely to complete study through 90-day follow-up

Keywords: stroke digital video spotrias
comparison of erector spinae plane block and penile block in hypospadias surgery

Conditions: Postoperative Pain; Analgesia

Summary: in this study, we aimed to compare ultrasound-guided sacral erector spinae plane block and dorsal penile block on postoperative analgesic effect in hypospadias surgery.

asai-ii, 1-9 years old patients with hypospadias diagnosis and operated in kahramanmaraş sütçü i̇mam university hospital and kocaeli university hospital were randomized with closed envelope technique and divided into two groups as penile block or erector spinae plane block. erector spinae plane block or penile block application (by gözen öksüz, can aksu) will be performed after the patients give standard general anesthesia and a laryngeal mask is applied. vital signs such as pulse, sp02, blood pressure will be monitored before, during and at the end of the operation. at the end of the operation and after the patient is awakened 5. min., 30 min. 1., 2., 4., 6., 12., 24. hourly flacc pain scores, number of analgesic use within 24 hours, patient family satisfaction (1: dissatisfied, 2: satisfied, 3: very satisfied), complication rates will be recorded.

Eligibility criteria:
inclusion criteria: * american society of anesthesiology classification (asa) i-ii, 1-9 years aged patients patients who scheuled elective hypospadias surgery in kahramanmaraş sütçü i̇mam university hospital and kocaeli university hospital exclusion criteria: * american society of anesthesiology classification (asa) iii-iv, patients with coagulopathy patients with infection at the injection site

Keywords: regional anaesthesia pediatric anesthesia erector spinae plane block penil block
immunopet targeting trophoblast cell-surface antigen 2 (trop-2) in solid tumors

Conditions: Tumor; Solid Tumor; Positron-Emission Tomography

Summary: the objective of the study is to construct a noninvasive approach 68ga-my6349 pet/ct to detect the trop-2 expression of tumor lesions in patients with solid tumors and to identify patients benefiting from trop-2 targeting antibody-drug conjugate treatment.

as a new trophoblast cell-surface antigen 2 (trop-2) targeting pet radiotracer, 68ga-my6349 is promising as an excellent imaging agent applicable to various cancers. in this research, subjects with various types of tumors underwent contemporaneous 68ga-my6349 and standard-of-care imaging (18f-fdg, 68ga-psma, or 68ga-dotatate pet/ct) either for an initial assessment or for recurrence detection. tumor uptake was quantified by the maximum standard uptake value (suvmax). the numbers of positive tumor lesions of standard-of-care imaging and 68ga-my6349 pet/ct were recorded by visual interpretation. the diagnostic accuracy of 68ga-my6349 was calculated and compared to standard-of-care imaging.

Eligibility criteria:
inclusion criteria: 1. adult patients (aged 18 years or older); 2. patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include mri, ct, tumor markers and pathology report); 3. patients who had scheduled both standard-of-care imaging (18f-fdg, 68ga-psma, or 68ga-dotatate pet/ct) and 68ga-my6349 pet/ct scans; 4. patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the clinical research ethics committee. exclusion criteria: 1. patients with pregnancy; 2. the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Keywords: tumor solid positron-emission tomography trop-2 diagnosis
comparison of intermittent fasting and caloric deficit for weight loss in women with polycystic ovarian syndrome

Conditions: Polycystic Ovarian Syndrome; Weight Loss; Intermittent Fasting

Summary: time restricted feeding (trf) has been emerging as a potential weight loss strategy that avoids major dietary changes but achieves strong effects. it also improves insulin sensitivity through increased human growth hormone. this effect helps to improve the root cause of weight gain and has additional benefits for women with pcos.


Eligibility criteria:
inclusion criteria: * pcos as described by rotterdam's criteria exclusion criteria: * endocrine disorders * diabetic * hypertensive * taking medications affecting weight or energy intake/energy expenditure in the last 6 months, including weight loss medications, antipsychotic drugs or other medications as determined by the study physician; * the body weight fluctuated more than 5% in recent 3 months. * liver and kidney dysfunction: renal impairment, creatinine clearance rate \< 30 ml/min/1.73 m2, transaminase increased, more than three times higher than the normal limit; * history of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction or stroke) in the past 6 months; * history of thyroid diseases; * pregnant * currently participating in weight loss programs or weight change in the past 3 months (\> 5% current body weight) * patients who cannot be followed for 16 months (due to a health situation or migration) * patients who are unwilling or unable to give informed consent
bevacizumab versus ranibizumab in age related macular degeneration

Conditions: Age Related Macular Degeneration

Summary: to report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab and ranibizumab in patients with choroidal neovascularization secondary to age-related macular degeneration.

we conducted a retrospective study of 500 eyes with choroidal neovascularization secondary to age-related macular degeneration who were treated with at least two (initial and one month after) intravitreal injection of 1.25 mg bevacizumab or 0.5 mg ranibizumab and had a follow-up of at least 3 months. patients underwent snellen visual acuity testing, optical coherence tomography (oct) imaging and ophthalmoscopic examination at baseline and follow-up visits.

Eligibility criteria:
inclusion criteria: * age ≥ 50 years * active primary or recurrent subfoveal lesion with cnv secondary to amd exclusion criteria: * prior treatment with any intravitreal drug in the study eye * prior treatment with verteporfin photodynamic therapy in the study eye * prior treatment with systemic bevacizumab * prior treatment with any intravitreal drug or verteporfin photodynamic therapy in the nonstudy eye within the 3 moths before the study entry * laser photocoagulation within 1 month before study entry in the study eye * previous participation in any clinical trial within 1 month before the entry of the study * subfoveal fibrosis or atrophy in the study eye * cnv in either of the two eye due to causes other than amd such as histoplasmosis or pathological myopia * retinal pigment epithelial tear involving the macula in the study eye * any concurrent intraocular condition in the study eye that could either require medical or surgical intervention during the 12 month study period or that could contribute to a loss of best corrected visual acuity over the 12 months study period (e.g. diabetic retinopathy, cataract, uncontrolled glaucoma). the decision on exclusion is to be based on the opinion of the local principal investigator. * active intraocular inflammation * vitreous hemorrhage in the study eye

Keywords: ranibizumab bevacizumab amd complications visual acuity oct age macular degeneration